Prosight Management, LP Alkermes Plc. Transaction History

Prosight Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$23.21 - $27.24 $1.39 Million - $1.63 Million	60,000 Added 27.91%	275,000 $6.63 Million
Q1 2024 May 15, 2024	BUY	$26.4 - $32.56 $5.28 Million - $6.51 Million	200,000 Added 1333.33%	215,000 $5.82 Million
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $1.17 Million - $1.43 Million	-50,000 Reduced 76.92%	15,000 $416,000
Q3 2023 Nov 14, 2023	SELL	$27.17 - $31.97 $2.24 Million - $2.64 Million	-82,554 Reduced 55.95%	65,000 $1.82 Million
Q2 2023 Aug 14, 2023	SELL	$28.34 - $33.63 $4.78 Million - $5.67 Million	-168,611 Reduced 53.33%	147,554 $4.62 Million
Q1 2023 May 12, 2023	SELL	$25.31 - $29.02 $641,760 - $735,831	-25,356 Reduced 7.42%	316,165 $8.91 Million
Q4 2022 Feb 14, 2023	SELL	$21.94 - $26.24 $3.52 Million - $4.21 Million	-160,629 Reduced 31.99%	341,521 $8.92 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $11 Million - $16 Million	502,150 New	502,150 $11.2 Million

358

180M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.12B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.